Risk factor
Very poor trading liquidity
Profitability factor
Very strong margins and returns
About
Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formasetin, a bone void filler; and intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names for use in orthopedic area. It also provides Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental grafts for use in orthopedic and dental areas. In addition, the company offers FormaAid, a collagen membrane; and E-TECH DENTISTAR II sterilizer and disinfectant for use in dental area, as well as HealiAid, a collagen wound dressing product for use in dental and wound dressing area. Further, it provides ophthalmic viscoelastic device under the ViscAid, PreviscAid, and BiVisc names; and Formaderm, a dermal filler injection for use in plastic surgery. Additionally, the company offers skincare products, including face, neck, body, limbs, and other masks; and make up remover, cleansing, exfoliating, toner, essence, men's care, sunscreen, body care, hand/foot care, and special care products. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan City, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair
Buy
Sell